Details for Patent: RE46375
✉ Email this page to a colleague
Which drugs does patent RE46375 protect, and when does it expire?
Patent RE46375 protects SYMPROIC and is included in one NDA.
This patent has twenty-three patent family members in eighteen countries.
Summary for Patent: RE46375
| Title: | 6,7-unsaturated-7-carbamoyl substituted morphinan derivative |
| Abstract: | A novel compound which is useful as an agent for treating and/or preventing emesis, vomiting and/or constipation.A compound represented by the formula (I): wherein R1 and R2 are each independently hydrogen, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted cycloalkyl, optionally substituted aryl etc., R3 is hydrogen, hydroxy, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, optionally substituted lower alkoxy etc., R4 is hydrogen or lower alkyl, R5 is hydrogen, lower alkyl, cycloalkyl lower alkyl or lower alkenyl, or a pharmaceutically acceptably acceptable salt, or a solvate thereof is provided. |
| Inventor(s): | Masanao Inagaki, Shin-ichiro Hara, Nobuhiro Haga, Yoshinori Tamura, Yoshihisa Goto, Tsuyoshi Hasegawa |
| Assignee: | Shionogi and Co Ltd |
| Application Number: | US15/064,538 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Delivery; Dosage form; |
Drugs Protected by US Patent RE46375
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bdsi | SYMPROIC | naldemedine tosylate | TABLET;ORAL | 208854-001 | Mar 23, 2017 | RX | Yes | Yes | RE46375 | ⤷ Start Trial | Y | Y | TREATMENT OF OPIOID-INDUCED CONSTIPATION | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: RE46375
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| PCT/JP2006/310231 | May 23, 2006 | |
International Family Members for US Patent RE46375
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 1889848 | ⤷ Start Trial | 300996 | Netherlands | ⤷ Start Trial |
| European Patent Office | 1889848 | ⤷ Start Trial | 2019C/533 | Belgium | ⤷ Start Trial |
| European Patent Office | 1889848 | ⤷ Start Trial | 122019000063 | Germany | ⤷ Start Trial |
| European Patent Office | 1889848 | ⤷ Start Trial | CA 2019 00035 | Denmark | ⤷ Start Trial |
| European Patent Office | 1889848 | ⤷ Start Trial | 38/2019 | Austria | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
